diaDexus Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Net Income before Extraordinaries
7,483.00
2,789.00
2,164.00
8,467.00
7,166.00
Depreciation, Depletion & Amortization
591.00
503.00
531.00
509.00
357.00
Other Funds
236.00
61.00
121.00
736.00
1,962.00
Funds from Operations
6,656.00
2,225.00
1,754.00
7,222.00
4,847.00
Changes in Working Capital
54.00
1,218.00
340.00
267.00
680.00
Net Operating Cash Flow
6,710.00
3,443.00
2,094.00
6,955.00
5,527.00
Capital Expenditures
1,083.00
605.00
302.00
211.00
22.00
Sale of Fixed Assets & Businesses
13.00
-
634.00
-
-
Purchase/Sale of Investments
6,978.00
5,974.00
747.00
-
-
Net Investing Cash Flow
8,048.00
5,771.00
1,079.00
207.00
22.00
Issuance/Reduction of Debt, Net
4,980.00
50.00
4,950.00
4,776.00
1,134.00
Net Financing Cash Flow
4,848.00
39.00
5,011.00
5,261.00
281.00
Net Change in Cash
9,910.00
2,367.00
3,996.00
1,901.00
5,830.00
Free Cash Flow
7,793.00
4,048.00
2,396.00
7,166.00
5,549.00
Other Sources
-
402.00
-
4.00
-
Change in Capital Stock
132.00
89.00
61.00
485.00
853.00

About diaDexus

View Profile
Address
349 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.diadexus.com
Updated 07/08/2019
Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. It operates through the following geographical segments: United States, Europe, and Rest of the World. Its portfolio intends to treat cardiovascular diseases.